


DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 10903 New Hampshire Ave, Bldg 51, Rm 4225 Silver Springs, MD 20993 (301) 796-3334 Fax: (301) 847 8738 Industry Information: www.fda.gov/oc/industry		DATE(S) OF INSPECTION 04/14/2016 - 04/22/2016 FEINUMBER 3007512884
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED TO: Mr. Francisco Molina Calle, Operations Director		
FIRM NAME Rovi Contract Manufacturing S.L.	STREET ADDRESS Calle Julian Camarillo 35	
CITY, STATE, ZIP CODE, COUNTRY Madrid 28037, Spain	TYPE ESTABLISHMENT INSPECTED Contract Manufacturer	
<p>This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.</p>		
DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:		
FACILITY AND EQUIPMENT SYSTEM		
OBSERVATION 1		
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.		
Specifically,		
Pressure differentials is not monitored within the classified areas where sterile products are manufactured. Your firm does not have a pressure differential monitoring device to record the pressure differential between the aseptic core ISO 5 and the surrounding ISO 7 clean room.		
The lack of a differential pressure monitoring device does not assure continuous monitoring and recording of any disruption in established (b) (4) within the aseptic core filling line during production of sterile drug products.		
OBSERVATION 2		
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.		
Specifically,		
A.		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Ademola O. Daramola, Investigator Xiomara Copeland, Microbiologist	DATE ISSUED 04/22/2016
		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
		PAGE 1 OF 3 PAGES

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT ADDRESS AND PHONE NUMBER 10903 New Hampshire Ave, Bldg 51, Rm 4225 Silver Springs, MD 20993 (301) 796-3334 Fax: (301) 847-8738 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 04/14/2016 - 04/22/2016
	FEI NUMBER 3007512884

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
TO: Mr. Francisco Molina Calle, Operations Director

FIRM NAME Rovi Contract Manufacturing S.L.	STREET ADDRESS Calle Julian Camarillo 35
CITY STATE ZIP CODE, COUNTRY Madrid 28037, Spain	TYPE ESTABLISHMENT INSPECTED Contract Manufacturer

Inadequate Sanitizer and Disinfectant Study: There is no assurance that the disinfectants used in your clean room facilities are effective against the specified bacteria, fungi and spore-forming microbes since your disinfectant efficacy studies did not meet the specification.

Specifically,

The coupons used in the following Disinfectant Efficacy Verification studies were not of the appropriate size of (b) (4) square required to demonstrate adequate log reduction during the predetermined contact times.

1. P372131205: Determination of bactericidal, fungicidal, and sporicidal activity of (b) (4) on (b) (4) surfaces.
2. P704140730: Determination of bactericidal, fungicidal, and sporicidal activity of (b) (4) on (b) (4) surfaces.
3. RE.11.ESP.007: Quantitative surface tests for the evaluation of bactericidal and fungicidal activity of (b) (4)
4. P372120701-A: Determination of bactericidal, fungicidal, and sporicidal activity of (b) (4) on (b) (4) surfaces.
5. P372130214-A: Determination of bactericidal activity of (b) (4) on (b) (4) and (b) (4) surfaces.
6. P704140729: Determination of bactericidal activity of (b) (4) on (b) (4) and (b) (4) surfaces.

B.

Failure to audit the contract microbiology laboratory (b) (4) performing disinfectant efficacy analyses used in your firm's clean room sanitization program. There is no assurance that the contract microbiology laboratory (b) (4) possesses the required expertise and personnel to successfully conduct the disinfectant efficacy tests.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Ademola O. Daramola, Investigator Xiomara Copeland, Microbiologist	DATE ISSUED 04/22/2016
	ADD XC	

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT ADDRESS AND PHONE NUMBER

10903 New Hampshire Ave, Bldg 51, Rm 4225
Silver Springs, MD 20993
(301) 796-3334 Fax: (301) 847-8738
Industry Information: www.fda.gov/oc/industry

DATE(S) OF INSPECTION

04/14/2016 - 04/22/2016

FEI NUMBER

3007512884

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED

TO: Mr. Francisco Molina Calle, Operations Director

FIRM NAME

Rovi Contract Manufacturing S.L.

STREET ADDRESS

Calle Julian Camarillo 35

CITY, STATE ZIP CODE, COUNTRY

Madrid 28037, Spain

TYPE ESTABLISHMENT INSPECTED

Contract Manufacturer

C.

Failure to provide Technicians with written procedures for equipment dismantling and cleaning during system changeover and aseptic core filling line machine cleaning activities.

Specifically,

On 4/19/2016, two clean room Technicians were observed to be without a written step-by-step procedures while dismantling and sanitizing the aseptic filling machine in line (b)(4) after production of (b)(4) ng batch # (b)(4)

QUALITY SYSTEM

OBSERVATION 3

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Low actual production yield was not investigated. Your firm could not provide evidence that investigations were performed, or any assessment of the production and filling process was made following documented determination of low actual yield at the conclusion of the filling phase of manufacturing of the drug product.

Specifically,

On August 5th, 2015 during the filling of Sterile (b)(4) USP (b)(4) ml - (b)(4) with batch number (b)(4) the calculated actual yield on the executed batch record was (b)(4) % against the specification of (b)(4) - (b)(4) %, however an investigation was not conducted to determine the root cause of the low yield and its potential impact on the product and production process.

EMPLOYEE(S) SIGNATURE

Ademola O. Daramola, Investigator
Xiomara Copeland, Microbiologist



DATE ISSUED

04/22/2016

**SEE REVERSE
OF THIS PAGE**